RSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that new data from several clinical trials, including the late-breaking MATRIX trial of ANGIOX® (bivalirudin), from across its cardiovascular product and pipeline portfolio will be presented at the 64th Annual Scientific Session of the American College of Cardiology, held March 14-16, in San Diego.
Help employers find you! Check out all the jobs and post your resume.
